iRhythm Technologies Inc (iRhythm) is a digital health company with a focus on the advancement of cardiac care. The company develops products and provides services to patients suffering from arrhythmias. The company’s product portfolio consists of long-term cardiac rhythm monitors, the Zio XT and Zio AT wearable patch-based biosensors. Its Zio service offers a platform for evaluating patients with suspected arrhythmias.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

iRhythm focuses its research and development (R&D) initiatives on enhancing the Zio System and Zio Services, expanding internationally, advancing technology offerings, optimizing customer workflows, improving data analytics, developing clinical evidence, and solidifying its presence in digital healthcare. The company aims to increase patient comfort, product quality, operational scalability, and security, while also exploring new patient populations and expanding its system portfolio and core technology offerings. The R&D unit of iRhythm employs engineering and research and development staff responsible for delivering future innovations and sustaining improvements. The unit focuses on continuous improvement and extensions to existing products and services, building infrastructure for international growth, advancing technology offerings, optimizing customer workflow, enhancing data analytics, developing clinical evidence, and exploring new systems and services for specific patient populations. In FY2024, the company spent US$71.5 million on R&D, which as a percentage of revenue, stood at 12% and grew 18.6% YoY. As of December 2024, iRhythm holds 46 issued patents from the US Patent Office, 13 from the Japanese Patent Office, four from the Australian Patent Office, five from the Canadian Patent Office, seven from the European Patent Offices, six from the Korean Patent Office, two from the Chinese Patent Office, and one from the Indian Patent Office.